Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity

In spite of newly emerging therapies and the improved survival of patients with non-Hodgkin lymphoma (NHL), relapses or primary refractory disease are commonly observed and associated with dismal prognosis. Although discovery of the anti-CD20 antibody rituximab has markedly improved outcomes in B-ce...

Full description

Saved in:

Bibliographic Details
Published in:	Blood Vol. 129; no. 16; p. 2246
Main Authors:	Bhatt, Shruti, Parvin, Salma, Zhang, Yu, Cho, Hyun-Mi, Kunkalla, Kranthi, Vega, Francisco, Timmerman, John M, Shin, Seung-Uon, Rosenblatt, Joseph D, Lossos, Izidore S
Format:	Journal Article
Language:	English
Published:	United States 20.04.2017
Subjects:	Animals Antibodies, Monoclonal, Murine-Derived - genetics Antibodies, Monoclonal, Murine-Derived - immunology Antigens, CD20 - genetics Antigens, CD20 - immunology Antineoplastic Agents - immunology Antineoplastic Agents - metabolism Antineoplastic Agents - pharmacokinetics Apoptosis - drug effects B-Lymphocytes - drug effects B-Lymphocytes - immunology B-Lymphocytes - pathology Cytotoxicity, Immunologic - drug effects Gene Expression Half-Life Humans Interferon-gamma - biosynthesis Interferon-gamma - immunology Interleukins - genetics Interleukins - immunology Killer Cells, Natural - drug effects Killer Cells, Natural - immunology Killer Cells, Natural - pathology Lymphoma, Non-Hodgkin - drug therapy Lymphoma, Non-Hodgkin - genetics Lymphoma, Non-Hodgkin - immunology Lymphoma, Non-Hodgkin - pathology Mice Mice, Inbred BALB C Mice, Transgenic Molecular Targeted Therapy Receptors, Interleukin-21 - genetics Receptors, Interleukin-21 - immunology Recombinant Fusion Proteins - genetics Recombinant Fusion Proteins - immunology Recombinant Fusion Proteins - pharmacokinetics Signal Transduction
ISSN:	1528-0020, 1528-0020
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!